Theralase Technologies Inc. V.TLT

potential Breakthrough Designation Approval

[floatinketucky]

$TLTFF-25 patients for potential Breakthrough Designation Approval-2021

Shawn Shirazi PhD, Chief Executive Officer, Theralase®, stated, "Another milestone has been reached by the Company with the addition of MU in Pennsylvania as a clinical study site. Theralase is focused on its target of enrolling and treating 11 additional patients in early 2021 for a total of 25 patients for potential Breakthrough Designation Approval and approximately 100 patients in 2021 / 2022."

https://www.accesswire.com/625524/Theralase-Launches-Third-Clinical-Study-Site-in-the-US-for-Phase-II-Bladder-Cancer-Clinical-Study
January 25, 2021

 

 

[floatinketucky]

$TLTFFOn the preliminary results, Theralase said, “The current interim analysis of the clinical data (with significant clinical data still pending and based on only 27 patients) demonstrates that Study II’s primary (33.3 per cent) and tertiary objectives (1 Severe AE) demonstrate a strong initial efficacy, strong durable efficacy and a high safety profile. There is insufficient data to comment on